Novel therapies of lupus nephritis

Current Opinion in Nephrology and Hypertension

Volumn 17, Issue 2, 2008, Pages 156-161

  Schieppati, Arrigo ^a,b   Remuzzi, Giuseppe ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

Lupus nephritis; Mycophenolate mofetil; Rituximab; Systemic lupus erythematosus

Indexed keywords

ABETIMUS; AZATHIOPRINE; CD40 ANTIGEN; CREATININE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; LEFLUNOMIDE; MONOCLONAL ANTIBODY IDEC 131; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR ALPHA;

CELL PROLIFERATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; GONADAL DISEASE; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; META ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; REMISSION; REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUGS, INVESTIGATIONAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MYCOPHENOLIC ACID; OLIGONUCLEOTIDES; TREATMENT FAILURE;

EID: 39149140990     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3282f4e54d     Document Type: Review

References (37)

1. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999; 10:413-424.
2. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL). Lupus nephritis: prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. Am J Kidney Dis 1992; 19:473-479.
3. Balow JE. Clinical presentation and monitoring of lupus nephritis. Lupus 2005; 14:25-30.
4. Howie AJ, Turhan N, Adu D. Powerful morphometric indicator of prognosis in lupus nephritis. QJM 2003; 96:411-420.
5. Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135:248-257.
6. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46:2121-2131.
7. Flanc RS, Roberts MA, Strippoli GF, et al. Treatment for lupus nephritis. Cochrane Database Syst Rev 2004; 1:CD002922.
8. Corna D, Morigi M, Facchinetti D, et al. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int 1997; 51:1583-1589.
9. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343:1156-1162.
10. Chan TM, Tse KC, Tang CS, et al. Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16:1076-1084.
11. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353:2219-2228.
12. McCune WJ. Mycophenolate mofetil for lupus nephritis. N Engl J Med 2005; 353:2282-2284.
13. Contreras G, Tozman E, Nahar N, Metz D. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 2005; 14 (Suppl 1):s33-s38.
14. Walsh M, James M, Jayne D, et al. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2007; 2:968-975. An excellent review summarizing the results of clinical trials with MMF.
15. Moore RA, Derry S. Systematic review and meta-analysis of randomized trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther 2006; 8:R182.
16. Haubitz M. Exploring new territory: the move towards individualised treatment. Lupus 2007; 16:227-231.
17. Glicklich D, Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis 1998; 32:318-322.
18. Levy Y, Sherer Y, George J, et al. Intravenous immunoglobulin treatment of lupus nephritis. Semin Arthritis Rheum 2000; 29:321-327.
19. Burt RK, Traynor A, Statkute L, et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 2006; 295:527-535.
20. Hainsworth JD, Burris HA 3rd, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000; 95:3052-3056.
21. Salama AD, Pusey C. Drug insight: rituximab in renal disease and transplantation. Nat Clin Pract Nephrol 2006; 2:221-230. This paper reviews all the present and potential uses of rituximab in renal diseases.
22. Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005; 52:501-513.
23. Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 2005; 17:550-557.
24. [No authors listed]. Abetimus: Abetimus sodium, LJP 394. BioDrugs 2003; 17:212-215.
25. Furie RA, Cash JM, Cronin ME, et al. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol 2001; 28:257-265.
26. Judge TA, Tang A, Turka LA. Immunosuppression through blockade of CD28:B7-mediated costimulatory signals. Immunol Res 1996; 15:38-49.
27. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994; 265:1225-1227.
28. Daikh DI, Finck BK, Linsley PS, et al. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol 1997; 159:3104-3108.
29. Boumpas DT, Furie R, Manzi S, et al., BG9588 Lupus Nephritis Trial Group. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003; 48:719-727.
30. Kalunian KC, Davis JC Jr, Merrill JT, et al., IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46:3251-3258.
31. Buhaescu I, Covic A, Deray G. Treatment of proliferative lupus nephritis - a critical approach. Semin Arthritis Rheum 2007; 36:224-237. A critical appraisal of the current trends in the treatment of lupus nephritis.
32. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an openlabel study. Arthritis Rheum 2004; 50:3161-3169.
33. De Bandt M, Sibilia J, Le Loet X, et al. Club Rhumatismes et Inflammation. Systemic lupus erythematosus induced by antitumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005; 7:R545-R551.
34. Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005; 20:1400-1406.
35. Prakash A, Jarvis B. Leflunomide: a review of its use in active rheumatoid arthritis. Drugs 1999; 58:1137-1164.
36. Cui TG, Hou FF, Ni ZH, et al. Treatment of proliferative lupus nephritis with leflunomide and steroid: a prospective multicenter controlled clinical trial. Zhonghua Nei Ke Za Zhi 2005; 44:672-676.
37. Jayne D. Current management of lupus nephritis: popular misconceptions. Lupus 2007; 16:217-220.